Presentations will highlight data demonstrating the broad clinical
utility, safety and potency of rezafungin to fight invasive fungal
infections
SAN DIEGO –
Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company
developing novel anti-infectives including immunotherapies, today
announced that data demonstrating the broad clinical utility and potency
of the company’s lead antifungal product candidate, rezafungin, will be
presented at IDWeek
2018, being held October 3-7 in San Francisco. Four separate IDWeek
presentations will focus on rezafungin, the only once-weekly antifungal
product candidate in development for the treatment and prevention of
life-threatening invasive fungal infections, and will include the
efficacy and safety results from Cidara’s Phase 2 STRIVE trial.
“We look forward to sharing the results of our Phase 2 STRIVE study in
an oral presentation at this important meeting,” said Jeffrey Stein,
Ph.D., president and chief executive officer of Cidara. “The data we
will present at IDWeek support our commitment to advance the development
of rezafungin as a potentially novel treatment and prophylactic agent
against deadly invasive fungal infections.”
The schedule of IDWeek presentations by Cidara Therapeutics and its
collaborators, which comprises one oral and three poster presentations,
is as follows:
Title: Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment
Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of
Candida
Date and Time: Friday, October 5, 2018, 12:30 p.m.-1:45
p.m. Pacific Time
Location: S Poster Hall
Poster Presentation
#1390
Session: PK/PD
Studies
Title: Rezafungin Clinical Safety and Efficacy in Patients with
Candidemia and/or Invasive Candidiasis in the Randomized, Double-blind,
Multicenter, Phase 2 STRIVE Study
Date and Time: Saturday, October
6, 2018, 9:30 a.m.-9:45 a.m. Pacific Time
Location: Room S 158
Oral
Presentation #1718
Session: Clinical
Trials that May Change Your Practice
Title: Activity of a Long-Acting Echinocandin, Rezafungin, Tested
against Invasive Fungal Isolates Collected Worldwide
Date and Time:
Saturday, October 6, 2018, 12:30 p.m.-1:45 p.m. Pacific Time
Location:
S Poster Hall
Poster Presentation #2400
Session: Treatment
of AMR Infections
Title: Effect of Rezafungin on QT Interval in Healthy Subjects
Date
and Time: Saturday, October 6, 2018, 12:30 p.m.-1:45 p.m. Pacific Time
Location:
S Poster Hall
Poster Presentation #2389
Session: Treatment
of AMR Infections
Copies of these presentations will be available on the Cidara website
following the meeting: www.cidara.com.
About Invasive Fungal Infections
Invasive fungal infections (IFIs) represent a serious threat to millions
of patients worldwide, resulting in more than 1.5 million deaths
annually and mortality rates ranging from 15 to 65 percent. These
infections continue to be a global health issue, especially for
critically ill patients in hospitals and patients with compromised
immune systems, including cancer and transplant patients. Approximately
90 percent of IFI-related deaths are associated with Candida, Aspergillus,
and Pneumocystis.
About Cidara Therapeutics
Cidara is a clinical-stage biotechnology company focused on developing
new anti-infectives that have the potential to transform the standard of
care and save or improve patients’ lives. The company is currently
advancing its novel echinocandin antifungal, rezafungin acetate,
formerly known as CD101 IV, through clinical trials. Rezafungin has
improved pharmacokinetics compared to existing echinocandins and the
potential for expanded utility across patient settings. It is the only
once-weekly product candidate in development for the treatment and
prevention of life-threatening invasive fungal infections. The company’s
Phase 2 STRIVE clinical trial of rezafungin met its primary safety and
efficacy objectives, and provides support for Cidara to initiate Phase 3
pivotal trials in the treatment of candidemia and invasive candidiasis
and the prophylaxis of invasive fungal infections. Cidara also is
leveraging its novel Cloudbreak™ platform to develop antibody-drug
conjugates for the treatment of multi-drug resistant Gram-negative
bacterial infections. Cloudbreak is the first immunotherapy discovery
platform designed specifically to create compounds that directly kill
pathogens and also direct a patient’s immune cells to attack and
eliminate bacterial, fungal or viral pathogens. Cidara is headquartered
in San Diego, California. For more information, please visit www.cidara.com.
Forward-Looking Statements
Statements contained in this press release regarding matters that are
not historical facts are “forward-looking statements” within the meaning
of the Private Securities Litigation Reform Act of 1995. Because such
statements are subject to risks and uncertainties, actual results may
differ materially from those expressed or implied by such
forward-looking statements. Such statements include, but are not limited
to, statements regarding the initiation of rezafungin Phase 3 pivotal
trials, the potential for rezafungin to be a novel treatment and
prophylactic agent against deadly invasive fungal infections, and
rezafungin’s potential for expanded utility across patient settings.
Risks that contribute to the uncertain nature of the forward-looking
statements include: the success and timing of Cidara’s preclinical
studies and clinical trials; regulatory developments in the United
States and foreign countries; changes in Cidara’s plans to develop and
commercialize its product candidates; Cidara’s ability to obtain
additional financing; Cidara’s ability to obtain and maintain
intellectual property protection for its product candidates; and the
loss of key scientific or management personnel. These and other risks
and uncertainties are described more fully in Cidara’s Form 10-Q most
recently filed with the United States Securities and Exchange
Commission. All forward-looking statements contained in this press
release speak only as of the date on which they were made. Cidara
undertakes no obligation to update such statements to reflect events
that occur or circumstances that exist after the date on which they were
made.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180912005041/en/
INVESTOR CONTACT:
Westwicke Partners, LLC
Robert H.
Uhl, 858-356-5932
Managing Director
robert.uhl@westwicke.com
or
MEDIA
CONTACT:
Sam Brown Inc.
Christy Curran, 615-414-8668
ChristyCurran@sambrown.com
